GENE ONLINE|News &
Tvardi Therapeutics to Present at Raymond James Biotech Innovation Symposium on April 2, 2026
Tvardi Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in the Raymond James Biotech Innovation Symposium. The event is scheduled to take place on April 2, 2026. Tvardi Therapeutics focuses on developing treatments targeting STAT3, a key signaling molecule implicated in various cancers and fibrotic diseases.
The symposium will bring together industry leaders, researchers, and investors to discuss advancements in biotechnology and innovative therapeutic approaches. Tvardi’s involvement highlights its ongoing efforts to advance its pipeline of STAT3 inhibitors currently under clinical development. Further details about the company’s presentation or specific contributions to the symposium have not been disclosed at this time.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: April 2, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
[Illustrations] The Diversity Deficit in Oncology Trials: When Enrollment Logic No Longer Reflects Real-World Patients
2026-04-16
Japanese Researchers Identify Stem Cell Dynamics in Vocal Fold Tissue Maintenance and Repair
2026-04-16
EVENT
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
